Czibere Akos reported option exercise involving 12,500 derivative units of Aktis Oncology, Inc. at $0.00 for $0 on Sep 23, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Medical Officer
Chief Medical Officer
Filed Sep 24, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
12,500Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
208,718Direct
Trade date
Sep 23, 2026Option exercise
Filed
Sep 24, 2026, 4:05 PM ET1-day reporting delay
Accession
0001193125-26-401014Code M · Transaction 228906
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 23, 2026Option exercise12,500$4.95$61,875Trade 228903
Sep 23, 2026Sell5,099$20.19−$102,972.78Trade 228904
Sep 23, 2026Sell7,401$21.03−$155,648.21Trade 228905
4 transaction rows in this filing. Joint filers share the same rows.

AKTS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AKTS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −5.7%30d −20%90d180d1y

Footnotes in full

F1: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2026. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6700 to $20.6500, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.6700 to $21.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4: 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.